{"id":2015,"date":"2024-10-29T08:30:00","date_gmt":"2024-10-29T12:30:00","guid":{"rendered":"https:\/\/research.ncsu.edu\/win\/?p=2015"},"modified":"2024-10-28T11:42:32","modified_gmt":"2024-10-28T15:42:32","slug":"win-harbright-raise-1-75m-for-sonovascular","status":"publish","type":"post","link":"https:\/\/research.ncsu.edu\/win\/win-harbright-raise-1-75m-for-sonovascular\/","title":{"rendered":"WIN and Harbright Raise Over $1.75M for SonoVascular"},"content":{"rendered":"\n\n\n\n\n
FOR IMMEDIATE RELEASE<\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n Raleigh, NC \u2013 October 29, 2024 <\/strong>\u2013 The Wolfpack Investor Network<\/a> (WIN) and Harbright Ventures<\/a> are excited to announce a follow-on investment of over $1.75M in SonoVascular<\/a>, a medical technology company that has developed SonoThrombectomy\u2122<\/a>, a novel, pharmaco-mechanical, ultrasound-facilitated, and thrombolytic-enhanced thrombectomy system for venous thromboembolism (VTE). VTE encompasses both Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is the third most common cardiovascular disease, causing approximately 300K deaths annually in the US.\u00a0<\/p>\n\n\n\n Founded in 2018 and leveraging intellectual property licensed from NC State<\/a>, SonoVascular\u2019s system combines four key components\u2014ultrasound, microbubbles, low-dose thrombolytic medications, and mechanical retrieval that helps resolve blood clots via delivery through an advanced intravascular catheter system. Designed to safely and effectively treat patients in the catheterization laboratory (cath lab), the SonoThrombectomy\u2122 System maximizes clot reduction, minimizes thrombolytic dosage and vascular trauma, and eliminates blood loss, which improves patient safety and eliminates the need for expensive ICU care.\u00a0<\/p>\n\n\n\n